The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ESLA | +20.55% | N/A | N/A | -86% |
| S&P | +12.16% | +74.91% | +11.82% | +53% |
Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.
No news articles found for Estrella Immunopharma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $42.63M | 1.0% |
| Net Income | -$4,801.15K | -42.2% |
| EBITDA | -$4,801.15K | -42.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.63M | -9.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -371.99% | 0.0% |
| Return On Invested Capital | -3165.63% | -2994.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$727.33K | -105.3% |
| Operating Free Cash Flow | -$727.33K | -105.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 56.60 | 236.48 | -18.96 | -6.99 | -170.38% |
| Price to Tangible Book Value | 56.60 | 236.57 | -18.96 | -6.99 | -170.38% |
| Price to Free Cash Flow TTM | 2.75 | 2.88 | - | ||
| Enterprise Value to EBITDA | -40.48 | -15.74 | -6.02 | -8.55 | -28.22% |
| Free Cash Flow Yield | 36.4% | 34.8% | - | ||
| Return on Equity | -314.6% | - | |||
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
